Flagship record · Pramlintide

Insulin Resistance in Type 1 Diabetes: Pathophysiological, Clinical, and Therapeutic Relevance.

reviewnarrative reviewcontextual mention

Scientific attribution

The source is a broad review of insulin resistance in type 1 diabetes rather than a primary study of pramlintide.

PMID: 39998445
DOI: 10.1210/endrev/bnae032
Sample size: Not captured in the structured review record
Population / model: However, the established lifestyle-related risk factors and peripheral insulin administration inducing glucolipotoxicity, hyperinsulinemia, hyperglucagonemia, inflammation, mitochondrial abnormalities, and oxidative stress cannot always fully explain insulin resistance in T1D, suggesting a phenotype distinct from type 2 diabetes.

Intervention / comparator

Aside from lifestyle modifications, continuous subcutaneous insulin infusion can ameliorate insulin resistance and hyperinsulinemia, thereby improving glucose toxicity compared with multiple injection insulin treatment.

Contradiction / qualification signals

However, the established lifestyle-related risk factors and peripheral insulin administration inducing glucolipotoxicity, hyperinsulinemia, hyperglucagonemia, inflammation, mitochondrial abnormalities, and oxidative stress cannot always fully explain insulin resistance in T1D, suggesting a phenotype distinct from type 2 diabetes.
However, considering the current issues of high cost, side effects, limited efficacy, and their off-label status, these agents in people with T1D are not widely used in routine clinical care at present.

Review status

This research library contains structured AI-assisted scientific review. AI-assisted review is not accountable human scientific approval. Inclusion here does not constitute publication approval, clinical guidance, efficacy proof, or automatic promotion of a scientific conclusion.

Loading research intelligence

Preparing the structured Flagship evidence library.